Scientists at the University of Southampton have found that the precise shape of an antibody makes a big difference to how it can stimulate the body's immune system to fight cancer, paving the way for much more effective treatments.
The latest types of treatment for cancer are designed to switch on the immune system, allowing the patient's own immune cells to attack and kill cancerous cells, when normally the immune cells would lie dormant.
Women and Cancer
Cancer is one of the frequently talked about and most feared disease that falls under the genre of lifestyle diseases that have evolved, rather rapidly, in the past two decades.
Advertisement
In a study, funded by Cancer Research UK and published in the journal Cancer Cell, the Southampton team have found that a particular form of antibody, called IgG2B, is much more effective at stimulating cancer immunity than other types. Unlike other forms of antibody, IgG2B can work independently without needing help from other immune cells, making it more active and able to work in all tissues of the body. The team have also been able to engineer antibodies that will be locked into the particular shape (called a locked B structure) that is most active, making them much stronger immune stimulators than previous drugs.
Dr Ann White, who led the study, comments: "We know that the immune system provides a natural protection against cancer, which can only grow by finding a way around our defences. Antibody treatments are now able to correct this problem for many types of cancer, but we still need them to work better.
![Pre-Cancerous Lesions]( "Pre-Cancerous Lesions")
Encyclopedia section of medindia gives general information about Pre Cancerous Lesions
"It is early days, but this important discovery could enable us to treat more cancers effectively. Our next task is to bring these novel IgG2B antibodies into trials for cancer patients and we are engineering ways to make them effective in the clinic."
The team is now working to discover why the IgG2 molecule works better in a locked B structure. To do this the molecule has been crystallised and an x-ray shone through it so the structure can be assessed. It is the first time that the IgG2 has been crystallised.
Professor Nic Jones, Cancer Research UK's chief scientist, said: "This research has zeroed in on how we can make immunotherapy treatments more effective against cancer. Energising the immune cells in our body and getting them to treat cancer cells as a threat gives us a better shot at beating cancer. Immunotherapy is part of the future of cancer treatment and it's important that we use our best immunotherapy weapons to fight the disease."
Source: Eurekalert
Pre-Cancerous Lesions
Encyclopedia section of medindia gives general information about Pre Cancerous Lesions
Advertisement
"It is early days, but this important discovery could enable us to treat more cancers effectively. Our next task is to bring these novel IgG2B antibodies into trials for cancer patients and we are engineering ways to make them effective in the clinic."
The team is now working to discover why the IgG2 molecule works better in a locked B structure. To do this the molecule has been crystallised and an x-ray shone through it so the structure can be assessed. It is the first time that the IgG2 has been crystallised.
Professor Nic Jones, Cancer Research UK's chief scientist, said: "This research has zeroed in on how we can make immunotherapy treatments more effective against cancer. Energising the immune cells in our body and getting them to treat cancer cells as a threat gives us a better shot at beating cancer. Immunotherapy is part of the future of cancer treatment and it's important that we use our best immunotherapy weapons to fight the disease."
Source: Eurekalert
Breast Cancer Management: Advances
The crab that invades the breast is no more a fear factor with all the advancements that medical science and customized protocols can fight breast cancer. the recent developments in the management of breast cancer.
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
The mechanism by which the kinases cause inflammation has been discovered by scientists.
Pancreatic cancer cases are on the rise. The biomarker approach could reduce the chance of developing pancreatic cancer.
New combination of medications trametinib and entinostat were found to decrease lung cancer in mice.
Combination treatment with TALZENNA and XTANDI was found to benefit prostate cancer patients, revealed study.
In leukemia patients, reduced amounts of dietary vitamin A is associated with a higher risk and severity of pancreatitis.